Dwight Owen

36PUBLICATIONS
222CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsLiquid biopsiesArtificial life and complex adaptive systems
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (36)

|Mar 09, 2026
Impact of proton pump inhibitors on immunotherapy is modulated by prior chemotherapy and linked to gut microbiome-immune cell signatures.

Annastasia Petouhoff, Ryan Hicks, Marium Husain

|Feb 03, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0.

Joshua E Reuss, Lyudmila Bazhenova, Nofisat Ismaila

|Feb 03, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0.

Sonam Puri, Natasha B Leighl, Nofisat Ismaila

|Dec 03, 2025
Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancer.

Dwight H Owen, Ruohan Wu, Lai Wei

|Oct 10, 2025
Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors.

Sandip H Patel, Songzhu Zhao, Mingjia Li

|Sep 29, 2025
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.

Alessio Cortellini, Valentina Santo, Leonardo Brunetti

Pageof 6

Frequent Collaborators

15 joint publications

Nofisat Ismaila

13 joint publications

Navneet Singh

10 joint publications

Natasha B Leighl

9 joint publications

Narjust Florez